James Cullen Biography and Net Worth
James G. Cullen has served as a member of our board of directors since December 2014, as our Lead Independent Director since January 2015 and as our Non-Executive Chairman since December 2017. During the last five years, Mr. Cullen has held board and committee positions with various companies. Mr. Cullen is currently a director of Keysight Technologies, which was spun out of Agilent Technologies, where he was previously a director. Mr. Cullen previously served as a director and chairman of the audit committee of Johnson & Johnson and as a director and member of the investment and finance committees of Prudential Financial. From 1993 to 2000, Mr. Cullen was President, Vice Chairman and Chief Operating Officer of Bell Atlantic Corporation (now Verizon). From 1989 to 1993, he was President and Chief Executive Officer of Bell Atlantic-New Jersey. Mr. Cullen holds a B.A. in Economics from Rutgers University and an M.S. in Management Science from the Massachusetts Institute of Technology.
What is James Cullen's net worth?
The estimated net worth of James Cullen is at least $166,368.16 as of May 31st, 2019. Mr. Cullen owns 25,361 shares of Avinger stock worth more than $166,368 as of September 28th. This net worth estimate does not reflect any other assets that Mr. Cullen may own. Learn More about James Cullen's net worth.
How do I contact James Cullen?
Has James Cullen been buying or selling shares of Avinger?
James Cullen has not been actively trading shares of Avinger within the last three months. Most recently, James Cullen sold 12 shares of the business's stock in a transaction on Tuesday, November 30th. The shares were sold at an average price of $8.55, for a transaction totalling $102.60. Learn More on James Cullen's trading history.
Are insiders buying or selling shares of Avinger?
In the last year, insiders at the medical device company sold shares 1 times. They sold a total of 14 shares worth more than $170.10. The most recent insider tranaction occured on March, 23rd when VP Nabeel Paul Subainati sold 14 shares worth more than $170.10. Insiders at Avinger own 7.1% of the company.
Learn More about insider trades at Avinger. Information on this page was last updated on 3/23/2023.
James Cullen Insider Trading History at Avinger
| Transaction Date | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/30/2021 | Sell | 12 | $8.55 | $102.60 | |  |
| 11/24/2021 | Sell | 2 | $9.30 | $18.60 | | |
| 2/4/2015 | Sell | 153 | $195.00 | $29,835.00 | | |
Avinger Company Overview
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. The company was incorporated in 2007 and is headquartered in Redwood City, California.
Read More
Volume
164,532 shs
Average Volume
658,302 shs
Market Capitalization
$4.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.62
